Fibralign set to bring new device option for secondary lymphedema

A young company developing a product to address secondary lymphedema, a chronic disease with no cure, stole the show at a venture competition held during a recent medical device conference. Working with Stanford University (Stanford, California), Fibralign (Sunnyvale, California) developed BioBridge, a surgical device designed to support the formation of new functional lymphatic vessels.

The company has completed a large animal study to validate the technology and is now preparing for a clinical study. Fibralign was voted the winner of the annual MedTech Innovator competition by an audience at the 22nd annual medical device conference hosted by law firm Wilson Sonsini Goodrich & Rosati (WSGR). The company won prizes valued at $150,000, including $100,000 in cash provided by RCT Ventures, $25,000 in cash provided by Johnson & Johnson Development Corporation, and $25,000 worth of lab space at Janssen Labs.

Read more: Medical Device Daily